Serum CRP Is a Better Early Marker for Response to Infliximab Induction Therapy Than Fecal Calprotectin in Patients With Moderate to Severe Ulcerative Colitis

被引：0
|
作者：
Brandse, Johannan F.
Jansen, Jeroen M.
Baars, Paul A.
Lowenberg, M.
Ponsioen, Cyriel
van den Brink, Gijs R.
D'Haens, Geert R.
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
212
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [31] An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
    Gibson, David J.
    Heetun, Zaid S.
    Redmond, Ciaran E.
    Nanda, Kavin S.
    Keegan, Denise
    Byrne, Kathryn
    Mulcahy, Hugh E.
    Cullen, Garret
    Doherty, Glen A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (02) : 330 - U170
  • [32] EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Sandborn, William
    Feagan, Brian
    Wolf, Douglas
    D'Haens, Geert
    Vermeire, Severine
    Hanauer, Stephen
    Ghosh, Subrata
    Southworth, Harry
    Harris, Sarah
    GASTROENTEROLOGY, 2021, 160 (03) : S8 - S9
  • [33] Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis Than the Lichtiger Index, CRP or Blood Leukocytes
    Schoepfer, Alain
    Beglinger, Christoph
    Straumann, Alex
    Safroneeva, Ekaterina
    Romero, Yvonne
    Armstrong, David
    Schmidt, Carsten
    Trummler, Michael
    Pittet, Valerie
    Vavricka, Stephan R.
    GASTROENTEROLOGY, 2012, 142 (05) : S114 - S114
  • [34] EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Sandborn, William
    Feagan, Brian
    Wolf, Douglas
    D'Haens, Geert
    Vermeire, Severine
    Hanauer, Stephen
    Ghosh, Subrata
    Southworth, Harry
    Harris, Sarah
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S6 - S6
  • [35] Induction with infliximab and a plant-based diet as first-line (IPF) therapy for moderate-to-severe to severe ulcerative colitis
    Chiba, Mitsuro
    Nakane, Kunio
    Tsuji, Tsuyotoshi
    Tsuda, Satoko
    Ishii, Hajime
    Ohno, Hideo
    Watanabe, Kenta
    Ito, Mai
    Obara, Yu
    Komatsu, Masafumi
    Sugawara, Takeshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 483 - 483
  • [36] Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better
    Kedia, Saurabh
    Ahuja, Vineet
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (11): : 966 - 967
  • [37] Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis
    Tanaka, Makoto
    Takagi, Tomohisa
    Naito, Yuji
    Uchiyama, Kazuhiko
    Hotta, Yuma
    Toyokawa, Yuki
    Kashiwagi, Saori
    Kamada, Kazuhiro
    Ishikawa, Takeshi
    Yasuda, Hiroaki
    Konishi, Hideyuki
    Itoh, Yoshito
    JGH OPEN, 2021, 5 (03): : 377 - 381
  • [38] Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial
    Bhairavi Balram
    Harshad Joshi
    Karen Wong
    Karen I. Kroeker
    Levinus A. Dieleman
    Brendan P. Halloran
    Daniel C. Baumgart
    Farhad Peerani
    Digestive Diseases and Sciences, 2021, 66 : 3985 - 3992
  • [39] The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate-to-severe ulcerative colitis
    Prymak, O.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S280 - S280
  • [40] Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial
    Balram, Bhairavi
    Joshi, Harshad
    Wong, Karen
    Kroeker, Karen I.
    Dieleman, Levinus A.
    Halloran, Brendan P.
    Baumgart, Daniel C.
    Peerani, Farhad
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (11) : 3985 - 3992
12345